Knowledge

Cosmetic pharmacology

Source 📝

45:, occasional patients seemed "better than well," and he discussed the ethical dilemmas that might result if similar medications were offered to individuals not afflicted with psychiatric disorders. Following these case reports, much controversy arose over the veracity and ethics of the cosmetic use of actual 40:
for the enhancement of beauty in conventional terms). In general, cosmetic psychopharmacology refers to the use of psychoactive medications by normal, healthy individuals for the purpose of enhancement rather than the treatment of a formal pathology. Kramer reported that with the antidepressant
52:
Opponents of cosmetic pharmacology believe that such drug usage is unethical and that the concept of cosmetic pharmacology is a manifestation of naive consumerism. Proponents, such as philosopher
63:, has argued that western medicine stands on the brink of a neuro-enhancement revolution in which people will be able to improve their memory and attention through pharmacological means. 231: 29:, refers to the use of drugs to move persons from a normal psychological state to another normal state that is more desired or better socially rewarded — e.g., from 261:
Bjorklund P (April 2005). "Can there be a 'cosmetic' psychopharmacology? Prozac unplugged: the search for an ontologically distinct cosmetic psychopharmacology".
56:, state that it is an individual's (rather than the government's or physician's) right to determine whether to use a drug for cosmetic purposes. 36:
The comparison is with surgery, in which the same intervention can be therapeutic (as in reparative work on burn victims) or cosmetic (as in
235: 154:
Chatterjee, Anjan (September 2004). "Cosmetic neurology: the controversy over enhancing movement, mentation, and mood".
314: 80: 60: 299: 71:
ethicist, has raised concerns about the possibility of employers mandating such enhancements for their workers.
139:
Caplan, Arthur (September 2003). "Is Better Best? A Noted Ethicist Argues in Favor of Brain Enhancement".
25: 191:"When the boss turns pusher: a proposal for employee protections in the age of cosmetic neurology" 190: 278: 212: 171: 85: 30: 270: 202: 163: 90: 68: 46: 20: 167: 64: 308: 274: 120:
Giannini AJ (2004). "The case for cosmetic psychiatry: Treatment without diagnosis".
53: 95: 37: 100: 207: 282: 216: 175: 33:
towards assertiveness and confidence or from slower to quicker cognition.
42: 300:
Society for the Advancement of Cosmetic Pharmacotherapy
8: 19:, a term coined in 1990 by the psychiatrist 206: 112: 59:Anjan Chatterjee, a neurologist at the 7: 168:10.1212/01.WNL.0000138438.88589.7C 14: 49:and other similar medications. 23:and popularized in his 1993 book 275:10.1111/j.1466-769X.2005.00213.x 230:Kirby, Jason (October 1, 2008). 255:Scientific articles via PubMed 232:"Going to Work on Smart Drugs" 1: 234:. Maclean's. Archived from 81:Performance-enhancing drugs 17:Cosmetic psychopharmacology 331: 61:University of Pennsylvania 189:Appel JM (August 2008). 208:10.1136/jme.2007.022723 238:on February 22, 2012 141:Scientific American 26:Listening to Prozac 315:Dermatologic drugs 122:Psychiatric Times 86:Cognitive liberty 322: 286: 248: 247: 245: 243: 227: 221: 220: 210: 186: 180: 179: 151: 145: 144: 136: 130: 129: 117: 91:Neuroenhancement 69:Brown University 330: 329: 325: 324: 323: 321: 320: 319: 305: 304: 296: 290: 260: 257: 252: 251: 241: 239: 229: 228: 224: 188: 187: 183: 153: 152: 148: 138: 137: 133: 119: 118: 114: 109: 77: 47:antidepressants 21:Peter D. Kramer 12: 11: 5: 328: 326: 318: 317: 307: 306: 303: 302: 295: 294:External links 292: 288: 287: 256: 253: 250: 249: 222: 181: 146: 131: 111: 110: 108: 105: 104: 103: 98: 93: 88: 83: 76: 73: 65:Jacob M. Appel 13: 10: 9: 6: 4: 3: 2: 327: 316: 313: 312: 310: 301: 298: 297: 293: 291: 284: 280: 276: 272: 269:(2): 131–43. 268: 264: 259: 258: 254: 237: 233: 226: 223: 218: 214: 209: 204: 200: 196: 192: 185: 182: 177: 173: 169: 165: 162:(6): 968–74. 161: 157: 150: 147: 142: 135: 132: 127: 123: 116: 113: 106: 102: 99: 97: 94: 92: 89: 87: 84: 82: 79: 78: 74: 72: 70: 66: 62: 57: 55: 54:Arthur Caplan 50: 48: 44: 39: 34: 32: 28: 27: 22: 18: 289: 266: 262: 240:. Retrieved 236:the original 225: 201:(8): 616–8. 198: 195:J Med Ethics 194: 184: 159: 155: 149: 140: 134: 125: 121: 115: 58: 51: 35: 24: 16: 15: 263:Nurs Philos 96:Neuroethics 38:rhinoplasty 242:October 6, 107:References 101:Nootropics 31:melancholy 156:Neurology 309:Category 283:15787908 217:18667652 176:15452285 75:See also 128:(7): 1. 281:  215:  174:  143:: 4–5. 43:Prozac 279:PMID 244:2008 213:PMID 172:PMID 67:, a 271:doi 203:doi 164:doi 311:: 277:. 265:. 211:. 199:34 197:. 193:. 170:. 160:63 158:. 126:21 124:. 285:. 273:: 267:6 246:. 219:. 205:: 178:. 166::

Index

Peter D. Kramer
Listening to Prozac
melancholy
rhinoplasty
Prozac
antidepressants
Arthur Caplan
University of Pennsylvania
Jacob M. Appel
Brown University
Performance-enhancing drugs
Cognitive liberty
Neuroenhancement
Neuroethics
Nootropics
doi
10.1212/01.WNL.0000138438.88589.7C
PMID
15452285
"When the boss turns pusher: a proposal for employee protections in the age of cosmetic neurology"
doi
10.1136/jme.2007.022723
PMID
18667652
"Going to Work on Smart Drugs"
the original
doi
10.1111/j.1466-769X.2005.00213.x
PMID
15787908

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.